UK Mounjaro Weight Loss Jab NHS Rollout: What GP Prescribing Rules Mean for Patients

The NHS Mounjaro rollout is now built around a two-cohort eligibility system, and GPs can only prescribe tirzepatide (the active ingredient in Mounjaro) if their practice has opted into the pathway agreed with their local Integrated Care Board. Since Cohort 2 launched on 23 June 2026, patients with a body mass index of 35 to 39.9 and at least four weight-related health conditions have joined the more severely obese patients already eligible under Cohort 1. This guide explains exactly what the tightened NHS Mounjaro eligibility rules mean, why supply is uneven across England, and what UK patients should ask their GP before pursuing treatment.

What Changed in NHS Mounjaro Prescribing Rules

From April 2026, NHS England folded tirzepatide prescribing into the 2026/27 GP contract, using new Quality and Outcomes Framework (QOF) indicators to formalise how practices identify and manage obesity in primary care. The move followed a 23 February 2026 announcement that GPs in England would receive up to £3,000 a year in bonus payments for prescribing weight-loss drugs such as Mounjaro, plus a further £1,000 for referring patients into structured weight-management programmes, backed by £25 million in ring-fenced funding.

The policy sits alongside NHS England's interim commissioning guidance implementing NICE technology appraisal TA1026 on tirzepatide, which set out the phased rollout GPs are now working to. Cohort 1 patients, those with a BMI of 40 or above (37.5 for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean patients) and at least four qualifying comorbidities, began accessing primary care prescribing first. Cohort 2, covering BMI 35 to 39.9 (32.5 to 37.4 with the same ethnicity adjustment) plus four comorbidities, followed from 23 June 2026.

Crucially, GP practice participation in the pathway remains optional. A practice can sit within an ICB that has switched on Cohort 1 and Cohort 2 prescribing and still decline to deliver it locally, meaning two patients with identical clinical profiles can face entirely different outcomes depending on which surgery they are registered with.

Who Is Eligible for Mounjaro on the NHS

Eligibility depends on meeting a BMI threshold, an ethnicity-adjusted BMI where relevant, and a minimum number of obesity-related comorbidities, not simply a patient's desire to lose weight. The qualifying conditions typically assessed include type 2 diabetes, hypertension, obstructive sleep apnoea, cardiovascular disease and dyslipidaemia, among others specified in NHS England's commissioning guidance.

• Cohort 1: BMI ≥40 (≥37.5 for specified ethnic groups) with 4 or more qualifying comorbidities.
• Cohort 2 (from 23 June 2026): BMI 35 to 39.9 (32.5 to 37.4 for specified ethnic groups) with 4 or more qualifying comorbidities.
• Ongoing prescribing requires clinical monitoring, dose escalation review and side-effect management, not a single sign-off.

Meeting these criteria on paper does not guarantee a prescription. Access still depends on whether the patient's ICB has commissioned the pathway and whether their specific GP practice has opted in, meaning eligibility and actual access are two separate hurdles for UK patients to clear.

Supply and Access Challenges Across England

Demand for Mounjaro is rising faster than many local systems can absorb, and prescribing costs vary sharply by region. NHS Business Services Authority data reported by Pulse Today (9 June 2026) show that tirzepatide items dispensed rose from 1.1 million to 3.1 million between 2024/25 and 2025/26, with total NHS spend reaching £574 million in a single year, a 377% increase, making it the highest-cost medicine on the NHS drugs bill and now equivalent to around 5% of total NHS medicine spend.

That spend is not evenly spread. The same data show NHS Cambridgeshire and Peterborough paying £420 per person for the medicine, more than double the £137 per person recorded in NHS South West London, illustrating a clear postcost lottery in how generously different ICBs fund the pathway.

The Royal College of GPs has reported that GP practices are seeing patient demand for Mounjaro consistently outpace local prescribing capacity (Royal College of GPs, 4 August 2026), a pattern that mirrors warnings already raised by the British Medical Association's GP committee. According to reporting in Pulse Today, the BMA's GP committee has said that some ICBs are withdrawing previously locally commissioned services for tirzepatide prescribing and monitoring, leaning instead on the new QOF indicators as an alternative form of provision, without necessarily funding the clinical workload that safe prescribing requires. In North East London, the local LMC has told practices they "should not feel pressured to deliver a service they are not commissioned to deliver," a direct response to concerns that secondary care teams are recommending tirzepatide and expecting GPs to manage it even where no funded local pathway exists.

Obesity specialists have separately cautioned that the QOF bonus scheme, while welcome, will have limited impact on overall access because eligibility itself remains tightly restricted; the payment changes how GPs are incentivised to prescribe within the existing criteria, not who qualifies for treatment.

The Social Impact: Who Is Losing Out

The gap between NHS eligibility and NHS access falls hardest on patients who cannot afford to go private. Private tirzepatide prescriptions in the UK commonly cost £150 to £250 or more per month, a sum that is simply out of reach for many low-income households, particularly given that obesity prevalence is itself higher in more deprived communities. Estimates cited in recent UK reporting put the proportion of English adults who are overweight or living with obesity at around 64.5% (2023/24 data), underlining how widespread the underlying health need is.

Patients registered with a practice in an ICB that has not commissioned the pathway, or whose own GP has not opted in, are effectively excluded regardless of how severe their obesity-related health conditions are. That creates a two-tier system: those with spare income can pay privately and start treatment within days, while NHS-eligible patients in under-resourced areas may wait months, or may never access the pathway locally at all. For patients with type 2 diabetes, sleep apnoea or cardiovascular disease, that delay is not cosmetic, it is a delay in treating conditions that carry their own serious long-term health risks.

News Analysis: Why the Rules Keep Tightening and Loosening at Once

The last seven months show NHS England trying to expand access and control cost simultaneously, and the tension between those two goals is now visible at ICB level. Adding tirzepatide prescribing to the 2026/27 QOF framework was designed to standardise how practices identify eligible patients and reward those who prescribe within the rules. But because QOF is a voluntary incentive scheme rather than a funded service contract, some ICBs appear to be using it as cover to withdraw the locally commissioned monitoring services that made safe prescribing practically possible for GPs.

The result, as reflected in RCGP's reporting of demand outpacing capacity and the BMA's warnings about unfunded pressure on practices, is that the national policy signal ("prescribe more, here is a bonus") and the local operational reality ("we have withdrawn the support service that let you do that safely") are pulling in different directions. For patients, this means the headline entitlement to Mounjaro on the NHS is only as good as their local ICB's willingness to fund the pathway behind it, a distinction that matters far more than the national eligibility criteria alone.

What Patients Should Ask Their GP

Before assuming Mounjaro is available, patients should confirm both their clinical eligibility and whether their specific practice can actually deliver the pathway locally.

• Ask directly whether your practice has opted into the NHS tirzepatide pathway, not just whether your ICB has approved it in principle.
• Confirm which cohort you fall into and whether your BMI and comorbidities have been formally recorded and coded, since informal self-assessment is not enough.
• Ask what monitoring, dose-escalation and side-effect support is commissioned locally, as this affects how safely treatment can continue.
• If declined locally, ask about referral routes to a specialist weight-management service or tier 3 clinic, which may offer an alternative NHS pathway.

Readers wanting wider context on NHS funding pressures affecting local services can find further analysis in Baba International's health coverage, while those weighing the cost of private treatment against other household priorities may find Baba International's finance coverage useful for budgeting decisions. For general reporting on UK consumer and policy issues, visit Baba International.

What To Do Next

Patients considering Mounjaro should take concrete steps rather than waiting for their local system to catch up with national policy.

1. Book a GP appointment specifically to discuss weight management and ask for a formal BMI and comorbidity assessment to establish which cohort applies.
2. Request written confirmation of whether your practice and ICB have an active, funded tirzepatide pathway before expecting a prescription.
3. If your practice has not opted in, ask for a referral to a tier 3 specialist weight-management service, which may offer an alternative NHS route.
4. If considering a private prescription as a bridge, get it from a UK-regulated pharmacy or clinic and disclose it to your GP so monitoring is joined up and side effects are managed safely.
5. Report side effects through the MHRA Yellow Card scheme, and raise ongoing supply or access problems with your practice manager or local Healthwatch, since patient-reported access gaps feed into future ICB commissioning decisions.

Related Reading

• UK Mental Health Crisis: How Long NHS Waiting Lists Impact Youth Services
• Europe's Migration Crisis: EU Tightens Borders Amid Influx Concerns
• UK MenB Vaccine Program: What University Students Need to Know
• European Drug Report 2026: Major Threats to EU Security from Trafficking

Frequently Asked Questions

Can any GP in England prescribe Mounjaro on the NHS?

No. Only GP practices that have opted into their ICB's commissioned tirzepatide pathway can prescribe Mounjaro on the NHS, and participation is optional, so availability varies significantly between practices even within the same area.

What BMI do I need to get Mounjaro on the NHS?

Patients generally need a BMI of 40 or above (37.5 for specified ethnic groups) under Cohort 1, or 35 to 39.9 (32.5 to 37.4 for specified ethnic groups) under Cohort 2, alongside at least four qualifying obesity-related health conditions.

Why is Mounjaro harder to get in some parts of the UK than others?

Access depends on whether an ICB has commissioned and funded the monitoring service GPs need to prescribe safely. NHS data show large regional variation in prescribing spend, and some ICBs have withdrawn locally commissioned support even as national incentives to prescribe have increased.

Is it safe to get Mounjaro privately instead of waiting for the NHS?

Private prescribing is legal through regulated UK pharmacies and clinics, but patients should always tell their GP so that monitoring, dose adjustment and side-effect management remain joined up with their wider NHS care.